EUVIMEDEUVIMED entdecken
Crossref

A CD36-Targeting Thermosensitive Berberine Nanogel Blocks Tumor Lipid Hijacking and Potentiates Anti-PD-L1 Immunotherapy in Triple-Negative Breast Cancer

Wanyu Jin, Shujun Xu, Hongyan Zhang, Yujie Li, Mengna Shi, Ninghui Ma, Xin Zhang, Lujia Zhu, Yang Xiong iD

Molecular Pharmaceutics · 02.02.2026 · 23 (2) · 958-974

DOI: 10.1021/acs.molpharmaceut.5c01378 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Pharmaceutics, online erschienen am 22.01.2026. Verfasst von Wanyu Jin und 8 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmaceutical Sciences, The First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, Zhejiang 310053, China. Hauptthemen laut MEDLINE: Berberine, Triple Negative Breast Neoplasms, CD36 Antigens, B7-H1 Antigen. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 51 Literaturangaben. Gefördert von: Zhejiang Traditional Chinese Medicine Administration, National Natural Science Foundation of China, Shaoxing Bureau of Science and Technology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The limited efficacy of programmed death-ligand-1 (PD-L1) monoclonal antibodies (aPD-L1) in triple-negative breast cancer (TNBC) is largely attributable to the immunosuppressive tumor microenvironment (TME). Notably, the abundance of cancer-associated adipocytes (CAAs) constitutes a distinctive feature of the TNBC microenvironment, contributing significantly to its immunosuppressive nature. CAAs upregulate cluster of differentiation 36 (CD36), a fatty acid translocase on tumor cells, thereby promoting excessive fatty acids (FAs) uptake and lipid droplet (LD) accumulation, which starve immune cells and reinforce immunosuppression through this metabolic adaptation. Berberine (BBR), a bioactive alkaloid derived from Rhizoma coptidis, has previously been shown to ameliorate lipid metabolism disorders through downregulation of CD36 in metabolic diseases such as hepatic steatosis. We therefore hypothesize that BBR inhibits CD36-mediated FAs uptake and reduces LD accumulation in tumor cells, representing a novel mechanism that remains unexplored in the context of TNBC. In this study, we demonstrated that BBR counteracts the tumor-promoting effects of CAAs in 4T1 cells by inhibiting CD36 upregulation and its mediated FAs uptake, thereby reducing CAA-induced LD accumulation and ultimately suppressing tumor cell proliferation. Furthermore, BBR remodeled the TME by enhancing CD8+ T cell recruitment and activity, while reducing immunosuppressive factors. In order to improve the sustained release of BBR at the tumor site and overcome its poor aqueous solubility, we created a thermosensitive hydrogel-based nanoparticle system (BBR-NPs-GEL). This injectable hydrogel demonstrated favorable thermosensitive gelation and shear-thinning behavior, making it suitable for localized administration. It exhibited a gelation temperature of 35.3 ± 0.2 °C and a sustained release profile with 52% of BBR released within 48 h. In 4T1Fluc tumor-bearing mice, BBR-NPs-GEL significantly suppressed tumor growth and remodeled the TME, as evidenced by increased infiltration of CD8+ T cells (+8.49%), activation of dendritic cells (+8.39%), and a shift toward M1-macrophages (+39.9%), accompanied by a reduction in M2-macrophages (-19.13%). Importantly, when combined with aPD-L1 therapy, the treatment elicited synergistic antitumor effects, resulting in enhanced tumor regression. This combination strategy effectively overcame metabolic immunosuppression and reversed immune resistance in TNBC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BerberineTriple Negative Breast NeoplasmsCD36 AntigensB7-H1 AntigenNanogelsFemaleHumansAnimalsMiceTumor MicroenvironmentCell Line, TumorImmunotherapyLipid Metabolism

Stichwörter der Autor:innen

CD36aPD-L1berberine nanoparticle thermosensitive hydrogellipid uptaketriple-negative breast cancer

Substanzen

BerberineCD36 AntigensB7-H1 AntigenNanogelsCD274 protein, humanCD36 protein, human

Autor:innen und Institutionen

  • School of Pharmaceutical Sciences, The First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, Zhejiang 310053, China.
  • Lanxi Hospital of Traditional Chinese Medicine, Jinhua, Zhejiang 321100, China.
  • School of Biological and Pharmaceutical Engineering, West Anhui University, Lu'an, Anhui 237012, China.
  • Affiliated Hospital of Shaoxing University, Shaoxing, Zhejiang 312000, China.

ORCID-Profile: Yang Xiong

Förderung

  • Zhejiang Traditional Chinese Medicine Administration
  • National Natural Science Foundation of China
  • Shaoxing Bureau of Science and Technology
  • Natural Science Foundation of Zhejiang Province
  • Zhejiang Chinese Medical University

Zitieren

APA

Jin, W., Xu, S., Zhang, H., Li, Y., Shi, M., Ma, N., Zhang, X., Zhu, L., & Xiong, Y. (2026). A CD36-Targeting Thermosensitive Berberine Nanogel Blocks Tumor Lipid Hijacking and Potentiates Anti-PD-L1 Immunotherapy in Triple-Negative Breast Cancer. Molecular Pharmaceutics, 23(2), 958-974. https://doi.org/10.1021/acs.molpharmaceut.5c01378

Vancouver

Jin W, Xu S, Zhang H, Li Y, Shi M, Ma N, et al. A CD36-Targeting Thermosensitive Berberine Nanogel Blocks Tumor Lipid Hijacking and Potentiates Anti-PD-L1 Immunotherapy in Triple-Negative Breast Cancer. Molecular Pharmaceutics. 2026;23(2):958-974. doi:10.1021/acs.molpharmaceut.5c01378

BibTeX
@article{Jin2026,
  author = {Jin, Wanyu and Xu, Shujun and Zhang, Hongyan and Li, Yujie and Shi, Mengna and Ma, Ninghui and Zhang, Xin and Zhu, Lujia and Xiong, Yang},
  title = {A CD36-Targeting Thermosensitive Berberine Nanogel Blocks Tumor Lipid Hijacking and Potentiates Anti-PD-L1 Immunotherapy in Triple-Negative Breast Cancer},
  journal = {Molecular Pharmaceutics},
  year = {2026},
  volume = {23},
  number = {2},
  pages = {958--974},
  doi = {10.1021/acs.molpharmaceut.5c01378}
}
Kostenlos starten →